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Transforming growth factor beta 1 (TGF𝛽1) is a key player in skeletal muscle degenerative and regenerative processes. We previously
showed that conditionally overexpressing TGF𝛽1 in skeletal muscles caused myofiber atrophy and endomysial fibrosis in mice.
However, the disease severity varied significantly among individual mice. While 40% of mice developed severe muscle pathology
and lost body weight within 2 weeks of TGF𝛽1 transgene induction in muscles, the rest showed milder or no phenotype. This study
aims at determining whether signal transducer and activator of transcription 3 (STAT3) plays a role in the phenotypic difference
and whether it can be activated by TGF𝛽1 directly in muscle cells. Our results show that while total STAT3 was not differentially
expressed between the two groups of mice, there was significantly higher pSTAT3 (Tyr705) in the muscles of the mice with severe
phenotype. Immunohistochemistry showed that pSTAT3 (Tyr705) was localized in approximately 50% of the nuclei of the muscles.
We further showed that TGF𝛽1 induced Tyr705 phosphorylation of STAT3 in C2C12 cells within 30 minutes of treatment while total
STAT3 was not affected. Our findings suggest that TGF𝛽1 alone can induce Tyr705 phosphorylation of STAT3 in skeletal muscle
cells and contribute to disease severity in transgenic TGF𝛽1 mice.

1. Introduction
TGF𝛽1 belongs to the TGF𝛽 superfamily and has been shown
to regulate a wide variety of biological processes, including
promotion of apoptosis, inhibition of cell growth, and induction of cell differentiation, migration, and extracellular matrix
(ECM) deposition [1, 2]. Several studies showed that persistent expression and activation of TGF𝛽1 act as negative regulator of muscle repair by inducing apoptosis in myoblasts,
suppressing muscle differentiation, and causing fibrosis in
the muscles [3–5]. TGF𝛽1 is believed to be responsible for
the ECM deposition in skeletal muscle [6–9], which leads to
endomysial and perimysial fibrosis in muscular dystrophies,
including Duchenne muscular dystrophy and congenital
muscular dystrophies [10–12]. Using animal models, we and
others demonstrated that TGF𝛽1 alone can cause muscle

atrophy and fibrosis in vivo [5, 13, 14]. However, TGF𝛽1 is
also recognized to play critical roles in muscle regeneration
process by recruiting macrophages to clean up the damaged
tissues after muscle injury and in muscle diseases [15].
The signal transducer and activator of transcription
(STAT) family are composed of latent cytoplasmic proteins
with a dual molecular role: signal transducer and transcription activator [16, 17]. One member of the STAT family,
STAT3, is expressed in most of tissue types and responds
mainly to IL-6, IL-10, and EGF signals [18, 19]. Phosphorylation of specific receptor tyrosine residue (Tyr705 or Ser727)
in response to ligand stimulation determines the activities of
STAT3. Tyr705 phosphorylation of latent cytoplasmic STAT3
promotes STAT3 homodimerization or heterodimerization
with other STATs, which leads to nucleus translocation and
DNA binding. Ser727 phosphorylation takes place at the
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C-terminal transactivation domain of STAT3 and allows
maximal activation of transcription of its target genes [20].
Within hours, STAT3 is exported back to the cytoplasm and
the signaling cascade is terminated [21–23]. Previous studies
showed that TGF𝛽1 directly activates STAT3 in other cell
types, including proximal tubular cells, T-cells, and pancreas
[24–26]. One study showed that STAT3 activation by TGF𝛽1
plays a major role in the pathological connective tissue
deposition in liver via the activation of connective tissue
growth factor (CTGF) in hepatic cells [27]. The same study
showed that STAT3 inhibition was sufficient to prevent CTGF
induction and fibrosis by TGF𝛽1. While it is known that
STAT3 activation in response to IL-6 stimulation plays major
roles in modulating muscle mass, to date there is no direct
evidence that TGF𝛽1 activates STAT3 in skeletal muscle cells.
To study the effects of TGF𝛽1 on muscle fibrosis and atrophy, we generated a tet-repressible muscle-specific TGF𝛽1
transgenic mouse model [5]. In this model, withdrawal of
oral doxycycline induces the expression of TGF𝛽1 transgene.
The study showed that TGF𝛽1 overexpression in skeletal
muscles causes muscle atrophy and endomysial fibrosis.
Interestingly, we observed that a subgroup of the TGF𝛽1
transgenic mice showed more severe muscle weight loss while
the rest exhibited milder pathology. The size of the myofibers
was significantly smaller and the endomysial fibrosis was
significantly higher in the subgroup with severe phenotypes,
suggesting that activation of additional signaling pathways
leads to more severe phenotypes. In this study, we investigated whether the STAT3 and phosphorylation of the protein
in the mice were associated with more severe phenotype.
In addition, we conducted an in vitro study using C2C12
myoblasts to determine whether TGF𝛽1 can activate STAT3
in muscle cells.

2. Materials and Methods
2.1. Mouse Model and Muscle Collection. All muscle samples
used in this were collected as described previously [5]. Briefly,
the tet-repressible muscle-specific TGF-𝛽1 transgenic mice
(TRE-TGF-𝛽1/mCK-tTA) were generated by crossing two
transgenic mouse lines (TRE-TGF-𝛽1 and mCK-tTA). The
TRE-TGF-𝛽1 line carries a porcine TGF-𝛽1 cDNA containing
a double mutation where cysteines at positions 223 and 225
are converted to serines, which is regulated by the tetO recognition element (TRE). The mCK-tTA line carries a construct
containing the tetracycline-controlled transactivator (tTA)
protein driven by a muscle-specific creatine kinase promoter
(mCK). The presence of doxycycline in cells inhibits binding
of tTA to the TRE and blocks TGF-𝛽1 transgene expression.
After crossbreeding the TRE-TGF-𝛽1 and mCK-tTA lines,
the pregnant female mice received drinking water with
doxycycline (200 𝜇g/mL in 5.0% sucrose) in order to suppress
the TGF-𝛽1 transgene expression in the pups in utero. After
weaning, all pups were maintained on water treated with
doxycycline until the transgene was induced. In this study,
doxycycline was removed from water to induce transgene
expression in the TRE-TGF𝛽1/mCK-tTA mice when the mice
were 6 weeks old. The muscles were collected 2 weeks after
the TGF𝛽1 transgene was induced. Littermates with only one
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of the transgenes, which do not express TGF𝛽1 were used as
controls.
2.2. Immunoblotting. Vastus lateralis muscles were sectioned
with a Leica CM 1900 cryostat (Walldorf, Baden-Wurttemberg, Germany). Thirty 10 𝜇m cryosections were lysed in
50 𝜇L of RIPA buffer (0.1% SDS, 1% NP40, 0.5% sodium
deoxycholate, 150 mM sodium chloride, and 50 mM TrisHCl
pH 7.5) for 30 minutes on ice, with protease inhibitor
cocktail (Complete, Roche, Mannheim, Germany) as well as
phosphatase inhibitor cocktail (PhosStop, Roche, Mannheim,
Germany). At the end of the incubation, the cell extracts
were centrifuged for 10 minutes (12,000 g) at 4∘ C. The amount
of protein was calculated using the Quick Start Bradford
Protein Assay Kit 1 (Bio Rad Laboratories, Hercules, CA).
Then 30 𝜇g of protein in NuPAGE LDS Sample Buffer
(Life Technologies, Grand Island, NY) and NuPAGE Sample
Reducing Agent (Life Technologies, Grand Island, NY) was
loaded to SDS-PAGE gel for immunoblotting analysis. The
primary antibodies used were pSTAT3 (Y705, 1 : 1000; Cell
Signaling Technology, Danvers, MA), pSTAT3 (S727, 1 : 1000;
Cell Signaling Technology, Danvers, MA), and Total STAT3
(1 : 1000; Cell Signaling Technology, Danvers, MA). Bound
antibodies were detected using ECL reagents. The results
were normalized to GAPDH (1 : 5000; Millipore, Billerica,
MA). Band intensity was evaluated by densitometry analysis,
normalized to its total content, and reported as fold increase
relative to respective control set as 1.
2.3. Immunofluorescence Staining. To detect pSTAT3
(Tyr705), muscle sections of 5 𝜇m were fixed in 4% paraformaldehyde, washed 3 times in 1x PBS, permeabilized
with 0.5% Triton X-100 for 10 minutes at room temperature,
and blocked with 5% goat serum. The slides were incubated
overnight at 4∘ C with the primary antibody against pSTAT3
Tyr705 (1 : 100 diluted in 5% goat serum). Secondary antibody
only was used as the negative control. After 3 washes in PBS
for 15 minutes each, the slides were incubated with the
secondary antibody Alexa Fluor 680 Donkey Anti-Rabbit
IgG (Life Technlogies, Grand Island, NY) for 1 hour at
room temperature and then washed again 3 times in 1x
PBS. Finally, the slides were mounted with the appropriate
mounting medium (ProLong Gold Antifade Reagent with
DAPI, Molecular Porbes, Life Technologies, Grand Island,
NY). Images of the tissue sections (20x, 40x) were taken
using Nikon Eclipse E800 microscope (Nikon, Chiyoda-ku,
Tokyo, Japan), RT slider camera (Diagnostic Instrument,
Sterling Height, MI), and SPOT advanced software.
2.4. Cell Culture and Treatment. Murine C2C12 myoblasts
were cultured in DMEM (Life Technologies, Grand Island,
NY) supplemented with 10% fetal bovine serum, 2 mM Lglutamine, and 100 U/mL penicillin/streptomycin at 37∘ C
in 5% CO2 . Cells were seeded in 6-well plates, and when
they were 70% confluent, they were induced to differentiate
with DMEM supplemented with 5% horse serum, 2 mM Lglutamine, and 100 U/mL penicillin/streptomycin at 37∘ C in
5% CO2 . TGF𝛽1 (R&D SYSTEMS, Minneapolis, MN) was
reconstituted at 20 𝜇g/mL in sterile 4 mM HCl containing

BioMed Research International

3
pSTAT3 (Tyr705)

Control

LO

EO
Normalized expression level

pSTAT3
(Tyr705)

7

Total
STAT3
GAPDH
pSTAT3
(Ser727)
GAPDH

∗

6
5
4
3
2
1
0

Control

pSTAT3 (Ser727)
2
Normalized expression level

Normalized expression level

EO

Total STAT3

2
1.5
1
0.5
0

LO

Control

LO

EO

1.5
1
0.5
0

Control

LO

EO

Figure 1: STAT3 phosphorylation level following TGF𝛽1 overexpression. Representative western blot of vastus lateralis muscle protein
samples of controls (𝑛 = 6), LO (𝑛 = 6), and EO (𝑛 = 6), with anti-phopsho-STAT3 (Tyr705), anti-phospho-STAT3 (Ser727), anti-totalSTAT3, and anti-GAPDH. Graphs show normalized expression values of pSTAT3 (Tyr705), pSTAT3 (Ser727), and total STAT3 normalized
to GAPDH ± SEM. All the values are normalized for the average of the control. ∗ indicates 𝑝 < 0.05.

1 mg/mL BSA, according to the manufacturer’s instructions.
C2C12 were then treated with TGF𝛽1 10 ng/mL after 7 days
of differentiation for 30 minutes, 2 hours, and 24 hours. The
cells were harvested and lysed in 30 𝜇L of RIPA buffer for
immunoblotting.
2.5. Statistical Analysis. Data are shown as mean ± SEM.
The Kruskal-Wallis test was used for determining statistical
significance among different groups of mice. Values of 𝑝 <
0.05 were considered significant. Student’s 𝑡-test was used for
determining statistical significance in treated cells. Values of
𝑝 < 0.05 were considered significant.

3. Results
3.1. Tyr705 Phosphorylation of STAT3 Is Associated with
the Severe Phenotypes Induced by TGF𝛽1. After the TGF𝛽1
transgene was induced for two weeks, approximately 40%
of mice developed severe phenotypes, including early body
weight loss and severe myofiber atrophy and fibrosis [5]. In
the study, the mice in this group were defined as mice with
early onset (EO). The rest of mice were grouped into the late
onset (LO) group. To determine whether STAT3 activation,
which is known to be involved in muscle atrophy induced by
IL-6, is involved in the variation of phenotypic presentations,
we first examined the protein expression of total STAT3 as
well as two phosphorylated STAT3, pSTAT3 (Tyr705), and
pSTAT3 (Ser727), in muscles collected from the two groups of

mice. Littermates of these mice, which did not express TGF𝛽1,
were used as baseline control.
Immunoblotting analysis showed that while the total
STAT3 was not significantly different among the EO, LO, and
control groups, pSTAT3 (Tyr705) was significantly induced in
the muscles of EO mice. No pSTAT3 (Tyr705) was detected in
the control or LO mice (Figure 1). The expression of pSTAT3
(Ser727) was observed in muscles of all 3 groups but no
significant difference among them. Variations of expression
levels of total STAT3 and pSTAT3 (Ser727) were observed
among different samples in all three groups. However, no
correlation between the total STAT3 and pSTAT3 (Ser727)
was observed.
3.2. pSTAT3 (Tyr705) Is Localized in the Nucleus of Myofibers
in the TGF𝛽1 Mice with Severe Phenotype. After examining
the phosphorylation status of STAT3, we investigated the
cellular localization of pSTAT3 (Tyr705). Immunofluorescence staining using a pSTAT3 (Tyr705)-specific antibody
showed that expression of pSTAT3 (Tyr705) was visible and
was localized in nuclei of the muscles of the EO mice, but
was not detectable in the LO mice and controls (Figure 2).
Approximately 50% of nuclei in the vastus lateralis muscles
of the EO mice were positive of pSTAT3 (Tyr705). When
costained with PAX7, a satellite cell marker, no pSTAT3
positive cells were costained. Our previous studies showed
no overt inflammatory infiltration in the muscles of these
mice [5]; therefore, most of the positive nuclei are likely
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Figure 2: Phospho-STAT3 (Tyr705) localization. Immunofluorescence of phospho-STAT3 (Tyr705) in vastus lateralis muscle. The panel
shows the cellular localization phospho-STAT3. While there is no or very few nuclei positive for phospho-STAT3 in control and LO samples,
phospho-STAT3 is clearly localized in the nuclei of EO mice muscle. Representative images of controls, LO, and EO at 40x magnification.
Phospho-STAT3 (Tyr705) = red; nuclei = DAPI.
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Figure 3: STAT3 phosphorylation level in differentiated C2C12. The panel shows STAT3 phosphorylation in differentiated C2C12 after
TGF𝛽1 10 ng/mL treatment. Protein extracted from C2C12 in control conditions, after 30 minutes, 2 hours, and 24 hours after TGF𝛽1
10 ng/mL treatment, with anti-phospho-STAT3 (Tyr705), anti-total STAT3, and anti-GAPDH. The graph shows fold changes of phosphoSTAT3 (Tyr705) normalized to GAPDH ± SEM. ∗∗ indicates 𝑝 < 0.01; ∗ ∗ ∗ indicates 𝑝 < 0.001.

myonuclei. To confirm that, we costained muscle sections
with CD14 and CD11b (monocyte/macrophage markers) and
CD3 (lymphocytes marker), respectively. In the few positive
cells, no nuclei were costained with pSTAT3 (Tyr705).
3.3. TGF𝛽1 Induces Tyr705 Phosphorylation of STAT3 in
C2C12 Myoblasts. In order to determine whether TGF𝛽1
can directly activate STAT3 in muscle cells, we treated the
murine myogenic cell line, C2C12, with recombinant TGF𝛽1
protein. The pSTAT3 (Tyr705) level was determined by

immunoblotting. The results showed that TGF𝛽1 significantly
increased pSTAT3 (Tyr705) 30 minutes after the treatment
(7.9-fold, 𝑝 < 0.001). The pSTAT3 (Tyr705) level descended to
baseline level after 2 hours of treatment. There was no change
of the total STAT3 protein during the time course examined
between the treated and control groups (Figure 3).

4. Discussion
In this study, we explored the relationship between TGF𝛽1
and STAT3 activation using a tet-repressible muscle-specific
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TGF𝛽1 transgenic mouse and C2C12 cells. The phosphorylation of the Tyr705 residue is required for STAT3 dimerization,
nuclear translocation, and DNA binding [28, 29]. Phosphorylation of the Ser727 residue is believed to promote STAT3
transcriptional activity through the enhanced recruitment of
transcriptional cofactors, which is not required for functional
activation of STAT3. Our data showed that overexpression
of TGF𝛽1 increased the amount of pSTAT3 (Tyr705) significantly in the EO mice but not in the LO mice. In addition,
the effect was mediated through the phosphorylation of
Tyr705 but not Ser727. While TGF𝛽1 mediated activation
of STAT3 in skeletal muscles was not reported previously,
TGF𝛽1 activated STAT3 by phosphorylating Tyr705 has been
reported in hepatic cells and a mouse model of hepatocellular carcinoma [27, 30]. Both of these studies reported
a direct activation of STAT3 by TGF𝛽1. Interestingly, a
recent study showed that hepatitis C virus (HCV) activates
TGF𝛽1 expression via STAT3 in hepatic stellate cells [31].
These findings suggested a potential postitive feedback loop
between TGF𝛽1 and STAT3 in the hepatic cells. In our TGF𝛽1
transgenic model, we previously reported that expression of
endogenous TGF𝛽1 was induced in mice with more severe
phenotypes, suggesting potential involvement of a positive
feedback loop [5]. Whether the STAT3 activation directly
modulates genes involved in muscle atrophy and fibrosis as
reported in previous studies or it induces endogenous TGF𝛽1
expression which is responsible for more severe phenotypes
needs to be further examined.
STAT3 was originally reported for its capacity to mediate
signaling predominantly from cytokines such as IL-6, IL11, leukemia inhibitory factor (LIF), and oncostatin M. It
is expressed in a large number of tissues and its activation drives the transcription of genes encoding proteins
involved in angiogenesis, inflammation, apoptosis, extracellular matrix deposition, and cellular signaling [32]. IL-6 is
well known for its crucial role in maintenance of skeletal
muscle metabolism [33–35]. IL-6-induced STAT3 has been
shown to promote satellite cells proliferation and myoblasts
differentiation. Acute and transient activation of STAT3 via
Tyr705 phosphorylation by IL-6 was reported to be associated
with muscle hypertrophy after 10 weeks of resistance training
in rats [36]. The hypertrophic effect was associated with the
early upregulation of the IL-6/STAT3 signaling pathway and
the downregulation of myogenic regulatory factors, including
Pax7, MyoD, Myf5, and myogenin, in the satellite cells.
While well controlled IL-6 expression plays a critical role
in maintaining the homeostasis of skeletal muscles, studies
also showed that persistent Tyr705 phosphorylation is associated with impairment of metabolism by negatively affecting
skeletal muscle insulin signaling and glucose uptake [37] and
is believed to be responsible for the IL-6-induced cancer
cachexia [33, 38]. Our study showed that overexpression of
TGF𝛽1 for 2 weeks induced pSTAT3 (Tyr705) in skeletal
muscles of the mice with severe phenotypes. Approximately
half of the nuclei were positive for pSTAT3 (Tyr705). Since
TGF𝛽1 was the only gene overexpressed in the mouse model
and is the driving force of the disease phenotype [5], the data
suggested that TGF𝛽1 is able to activate the STAT3 signaling
directly. However, whether IL-6 signaling is involved in

5
the process is not clear and needs further investigation. To
examine the possibility and demonstrate that TGF𝛽1 directly
activates STAT3 in skeletal muscle cells, we treated the C2C12
cells with recombinant TGF𝛽1 and examined the activation
of STAT3 at 3 time points (30 min, 2 hrs, and 24 hrs) within
24 hours. Our findings showed that the pSTAT3 Tyr705
was transiently activated within 30 minutes. This result is
in agreement with a recent study using immortalized rat
hepatic stellate cells (HST) [27]. In this study, it was also
shown that JAK1 is necessary for the Tyr705 phosphorylation
and activation of STAT3. Knockdown of JAK1 but not JAK2
or Tyk2 is sufficient to attenuate TGF𝛽1 mediated STAT3
activation. STAT3 is canonically activated by JAKs (JAK1,
JAK2, JAK3, and Tyk2), which in turn are activated by a large
number of cytokine and growth factors, including IL-10, IL6, and EGF, and it is well known to play a crucial role in
myogenic proliferation and differentiation [39, 40]. Whether
the activation of STAT3 is mediated through JAK1 in our
models needs to be investigated further.

5. Conclusion
Our study demonstrated that pSTAT3 (Tyr705) activation is
associated with severity of phenotypes of our mouse model
overexpressing TGF𝛽1 in skeletal muscles. The activated
STAT3 was localized in the nuclei of myofibers, suggesting
transcription activation. Both in vivo and in vitro data
suggested that pSTAT3 (Tyr705) can be induced by TGF𝛽1.
These data thus point to a novel signaling pathway that
may modulate and contribute to the molecular and cellular
mechanism of skeletal muscle fibrosis and atrophy in various
diseases.

Disclaimer
The content is solely the responsibility of the authors and does
not necessarily represent the official views of the National
Institutes of Health.

Conflict of Interests
The authors confirm that there is no conflict of interests.

Acknowledgments
Research reported in this paper was supported by the Department of Defense under Award no. W81XWH-10-1-0659 and
the NIH/NICHD under Award no. 1R24HD050846. Yi-Wen.
Chen was partially supported by NIH/NIAMS under Award
no. 1R01AR052027. Carsten G. Bönnemann is supported by
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